Phosphodiesterase: An Interface Connecting Cognitive Deficits to Neuropsychiatric and Neurodegenerative Diseases

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|21|3|303-316

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.21, Iss.3, 2015-01, pp. : 303-316

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Involvement of Heme Oxygenase-1 in Neuropsychiatric and Neurodegenerative Diseases

By  

Current Pharmaceutical Design, Vol. 24, Iss. 20, 2018-06 ,pp. : 2283-2302

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase as a New Therapeutic Target for the Treatment of Spinal Cord Injury and Neurodegenerative Diseases

By  

Current Medicinal Chemistry, Vol. 21, Iss. 24, 2014-08 ,pp. : 2830-2838

Bentham Science Publishers

Access to resources Recommend Favorite

Biochemical, Biomedical and Metabolic Aspects of Imidazole-Containing Dipeptides with the Inherent Complexity to Neurodegenerative Diseases and Various States of Mental Well-Being: A Challenging Correction and Neurotherapeutic Pharmaceutical Biotechnology for Treating Cognitive Deficits, Depression and Intellectual Disabilities

By  

Current Pharmaceutical Biotechnology, Vol. 15, Iss. 8, 2014-08 ,pp. : 738-778

Bentham Science Publishers

Access to resources Recommend Favorite

Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases

By  

Current Pharmaceutical Design, Vol. 18, Iss. 7, 2012-03 ,pp. : 875-883

Bentham Science Publishers

Access to resources Recommend Favorite

Histamine H3 Antagonists for Treatment of Cognitive Deficits in CNS Diseases

By  

Current Topics in Medicinal Chemistry, Vol. 10, Iss. 2, 2010-02 ,pp. : 153-169

Bentham Science Publishers

Access to resources Recommend Favorite